/HALB

HALB Stock - Halberd Corporation

Q: What is the analyst price target for HALB?

Analyst price target information is not currently available for HALB.

Q: What is HALB's market cap?

Market capitalization information is not currently available for HALB.

Healthcare|Biotechnology|OTC

$0.00+8.33%

+$0.00 (+8.33%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for HALB

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2021

FY2022

FY2023

FY2024

FY2025

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.36

52W High$0.00

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	N/A	$999	$2,725	$8,020	$5,238
Gross Profit	$-549	$-207	$1,320	$7,806	$943
Gross Margin	N/A	-20.7%	48.4%	97.3%	18.0%
Operating Income	$-18,665	$-75,050	$-447,194	$-1,618,631	$-855,679
Net Income	$-20,071	$-79,676	$-454,072	$-1,624,744	$-861,537
Net Margin	N/A	-7975.6%	-16663.2%	-20258.7%	-16447.8%
EPS	$0.00	$-0.00	$-0.00	$-0.00	$-0.00

Company Overview

Halberd Corporation, a biotech company, develops treatments for neurodegenerative diseases. It offers treatments for post traumatic stress disorder/chronic traumatic encephalopathy, Alzheimer's and Parkinson's disease, cancer, blood-borne, and cerebrospinal fluid related diseases. The company was incorporated in 2009 and is based in Jackson Center, Pennsylvania.

Visit Website